Author

Maan Alwan

Observed name: Alwan, Maan

Observed institution: Nicolae Testemițanu State University of Medicine and Pharmacy

OpenAlex ID: A5035246346

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

2023 · John F. Seymour, Chan Yoon Cheah, et al. · Blood · 70

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

2024 · Constantine S. Tam, Anna Maria Frustaci, et al. · Blood · 8

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

2023 · David Lavie, Vincent Ribrag, et al. · Blood · 7

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

2022 · Rosa Ayala, Nieves Lopez, et al. · Blood · 4

MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

2023 · Rosa Ayala, Nieves Lopez, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

POSTER: MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

2023 · Rosa Ayala, Nieves Lopez, et al. · Clinical Lymphoma Myeloma & Leukemia

S213: Bms-986158, a Potent Bet Inhibitor, as Monotherapy and in Combination With Ruxolitinib or Fedratinib in Intermediate- or High-risk Myelofibrosis (mf): Results From a Phase 1/2 Study

2023 · Rosa Ayala, Nieves Lopez, et al. · HemaSphere

Works count: 8

Citation count: 91

H-index: 4

I10-index: 1